Animation Gif

Not actual patients.

A clear choice for EAR-RESISTIBLE patients

Star Icon

CIPRODEX® Otic is the first and only FDA-approved antibiotic/anti-inflammatory for both acute otitis externa (AOE) and acute otitis media with tympanostomy tubes (AOMT) caused by susceptible isolates of certain microorganisms in patients aged ≥ 6 months—with high clinical cure rates1,2

Animation Gif

Not actual patients.

Carmen Image

Not an actual patient.

The average out-of-pocket cost for CIPRODEX® Otic is $34

Eligible, commercially insured patients may pay as little as $30* for their prescription with the CIPRODEX® Otic co-pay card.

Help your patients save
Man ICon

1 in 123 people gets AOE every year3,4

Learn more about AOE Learn more about AOE
83 Percent Pie Chart ICon

83% of children with tympanostomy tubes

experienced at least one episode of otorrhea after 18 months5

Learn more about AOMT Learn more about AOMT

*Terms and Conditions: Valid only for those with commercial insurance. Offer not valid under Medicare, Medicaid, or any other federal or state program, for cash-paying patients, or where plan reimburses you for the entire cost of your prescription drug. Eligible, commercially insured patients may pay as little as $30 in out-of-pocket expenses for each 7.5mL bottle of CIPRODEX® (ciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension with a maximum benefit per bottle of $170. Offer good for up to three (3) 7.5mL bottles of CIPRODEX® Otic for a single patient. If insured patient reaches maximum benefit per bottle, patient will be responsible for the difference. Offer is not valid where prohibited by law. Valid only in the US, USVI, Guam and Puerto Rico. This program is only valid for those patients 6 months and older. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. This card is the property of Novartis Pharmaceuticals Corporation and must be returned upon request. Novartis reserves the right to rescind, revoke, or amend the program without notice. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt of program rewards, if necessary, to any commercial insurer.

Plus Icon Plus Icon

INDICATIONS AND IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: CIPRODEX® Otic should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones.

Potential for Microbial Overgrowth with Prolonged Use: Prolonged use of CIPRODEX® Otic may result in overgrowth of non-susceptible bacteria and fungi. If the infection is not improved after one week of treatment, cultures should be obtained to guide further treatment. If such infections occur, discontinue use and institute alternative therapy.

Continued or Recurrent Otorrhea: If otorrhea persists after a full course of therapy, or if two or more episodes occur within six months, further evaluation is recommended to exclude an underlying condition such as cholesteatoma, foreign body, or a tumor.

ADVERSE REACTIONS

The most commonly reported adverse reactions in clinical trials were:

INDICATIONS and USAGE

CIPRODEX® Otic is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in:

DOSAGE

For additional information on CIPRODEX® Otic, please click here for the full Prescribing Information.

References: 1. CIPRODEX [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2015. 2. US Food and Drug Administration. Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book). 38th ed. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436.pdf. Published 2018. Accessed July 12, 2018. 3. Rosenfeld RM, Schwartz SR, Cannon CR, et al. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg. 2014;150(suppl 1):S1-S24. 4. Centers for Disease Control and Prevention. Estimated burden of acute otitis externa—United States, 2003-2007. MMWR Morb Mortal Wkly Rep. 2011;60(19):605-609. 5. Ah-Tye C, Paradise JL, Colborn DK. Otorrhea in young children after tympanostomy-tube placement for persistent middle-ear effusion: prevalence, incidence, and duration. Pediatrics. 2001;107(6):1251-1258.